For the target price: rather use DCF or a multiple?
Would you say using a DCF or a multiple (P/E, EV/EBITDA, etc.) is more common nowadays?
I feel like a DCF is way too subjective and can be manipulated greater
Would you say using a DCF or a multiple (P/E, EV/EBITDA, etc.) is more common nowadays?
I feel like a DCF is way too subjective and can be manipulated greater
+72 | Q&A - Buyside Equity Research Analyst/PM | 27 | 6d | |
+31 | How the heck do you learn all of this stuff? | 5 | 3d | |
+28 | Getting Frustrated | 10 | 3w | |
+27 | My experience on the sell side | 20 | 1w | |
+22 | What’s my next move? | 6 | 2w | |
+18 | Biotech ER vs IB | 16 | 3w | |
+14 | Am i fairly compensated? | 7 | 3h | |
+14 | Data Science to PM | 8 | 19h | |
+14 | Heard they don’t model at Oppenheimer | 10 | 1w | |
+13 | ER time line and ways to break in help | 17 | 2w |
Career Resources
Multiples are much more common. While DCF is theoretically sound, it's not the best way to communicate a company's valuation without going through all your assumptions. Multiples are a language that everyone speaks.
Most SS ER price targets are for a year out which isn't exactly conducive to a DCF
Multiples in my opinion are actually very sensitive to all sorts of distortions: rumours about a take-private, bear/bull markets, etc. Would always do a DCF, at least as a sanity check.
Corrupti ut inventore laborum maxime eos. Omnis eveniet ab eveniet repudiandae. Et laudantium quaerat pariatur aut velit quis in quia. Et corporis omnis quia sed voluptas consequatur voluptas.
Voluptates impedit iste veritatis amet. Eligendi nihil ullam rerum illo provident hic fugiat. Cum optio deserunt delectus minima non minima facere.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...